From Baseline News Today

Treatment-Related Early Increase in Serum TTR is Associated With Lower Cardiovascular Mortality in ATTR-CM: Insights From ATTRibute-CM Amrut...

Early Increase in Serum Transthyretin Level Is an Independent Predictor of Improved Survival in ATTR Cardiomyopathy: Insights From Acoramidis Phase 3 Study ATTRibute-CM ...

Study Achieves Primary and all Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight at all Doses as Compared to Placebo Up to 13.1% Placebo-Adjusted Mean Weight...

– Treatment with VX-548 led to statistically significant improvement in pain compared to placebo as well as a clinically meaningful reduction in pain from baseline in both the abdominoplasty and...

Preventing Chronic Disease (PCD) is a peer-reviewed electronic journal established by the National Center for Chronic Disease Prevention and Health Promotion. PCD provides an open exchange of information and knowledge among researchers, practitioners, policy makers, and others who strive to improve the health of the public through chronic disease prevention.

Presentation Highlights Previously Reported Weight Loss of up to 7.8% From Baseline as well as Significant Liver Fat, Plasma Lipid Reductions following 28 Days of Treatment with VK2735 SAN DIEGO,...

FDA has posted an Addendum to Briefing Document on its website that was circulated to members of the AdCom ... | May 9, 2023

/PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...

First placebo-controlled efficacy study completed to date exploring a short-duration psychedelic for depression demonstrates rapid and durable response Primary endpoint met with a statistically significant

First placebo-controlled efficacy study completed to date exploring a short-duration psychedelic for depression demonstrates rapid and durable response ...